Product Information
Registration Status: ActiveSIN15248P
HUMIRA SOLUTION FOR INJECTION 40MG/0.4ML (SYRINGE AND PEN) is approved to be sold in Singapore with effective from 2017-05-26. It is marketed by ABBVIE PTE LTD, with the registration number of SIN15248P.
This product contains Adalimumab 40mg in the form of INJECTION, SOLUTION. It is approved for SUBCUTANEOUS use.
This product is manufactured by Vetter Pharma-Fertigung GmbH & Co. KG (Ravensburg) in UNITED STATES, andAbbVie Biotechnology Ltd in GERMANY.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
Adalimumab is a human monoclonal antibody against TNF-alpha. It is produced by recombinant DNA technology using a mammalian cell expression system. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons [L1306].
Indication
For treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease.
Mechanism of Action
Adalimumab binds to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement.
Clearance
* 12 mL/hr [RA patients with dose 0.25-10 mg/kg]
Active Ingredient/Synonyms
Adalimumab (genetical recombination) | adalimumab-adbm | adalimumab-atto | Adalimumab |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.